Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT05440773 |
| Other study ID # |
xxxxx |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
April 2023 |
| Est. completion date |
February 2024 |
Study information
| Verified date |
June 2022 |
| Source |
Université Catholique de Louvain |
| Contact |
Suh Nchang Abenwie, MSc. MPH. |
| Phone |
+237 676786985 |
| Email |
abenwie.suhnchang[@]uclouvain.be |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The study is a Phase 2 randomized controlled, partial-blind, parallel group study in
plasmodium infected asymptomatic adults 18 years and older, with 8 study arms. It will use
the adapted Zelen design, which has two steps in the consent process. In the first step,
there is an informed consent from all participants for a cohort lifestyle study. According to
this consent, participants are randomized without knowledge about the detailed protocol.
In the second step, only participants from the intervention group will receive the
information about the intervention and the second consent will be obtained from them. The
participants who will decline to participate to an intervention will continue in the cohort
study, as the control group.
Description:
This study will use the adapted Zelen design which has two steps in the consent process. At
step one, informed individuals (students and workers) will be invited to participate in a
screening and cohort survey on asymptomatic malaria, aimed at understanding the comportment
of plasmodium parasite in asymptomatic plasmodium carriers over time. After informed consent
is obtained during the first encounter (day 0), baseline assessments will be done and
sociodemographic variables, clinical/medical history, physical assessment, prior medications
information and participants' contact details will be recorded. Blood samples will be
collected from each participant and examined for the presence of parasites (Gametocytes)
using malaria rapid diagnostic test kit (mRDT). RDT positive samples will be re-examined with
qPCR (quantitative polymerase chain reaction) and direct microscopy for confirmation. The
qCPR will be repeated for negative samples and participants excluded if still negative. All
qPCR positive samples will be further analyzed with rt PCR (real time polymerase chain
reaction), for parasite quantification and specific stage identification, targeting specific
parts of the gametocyte genes. Participants who fulfil the inclusion criteria will be
randomly allocated in the 8 study arms in a 2:2:2: 2:2:2:1:1 ratio for the 6 treatment and 2
control arms, respectively. In the second step, only participants from the intervention
groups will receive the information about the intervention and a second consent will be
obtained from them (TG1-TG7). Treatment administration will be based on the allocation arm.
The treatments will consist of Artemisia afra tea infusions for the 6 trial arms versus
flavored placebo infusions and desired regular tea for the 2 control arms. The participants
who will decline to participate to an intervention will continue in the cohort study, as a
control group on regular tea (TG 8).
During 4 consecutive weeks, all participants will be tested using rtPCR once a week on Day 7,
14, 28 and 35, in order to assess gametocyte elimination rate with teas. During the 4 weeks,
participants will be monitored and encouraged to comply to the prescribed treatment, and also
monitored/assessed for any clinical symptoms and treatment reactions (ASEs and AE).
